- Home
- TELO
TELO
TELOMIR PHARMACEUTICALS INC
as 05-15-2025 9:59am EST
Stocks
| Founded: | 2021 | Country: | United States |
| Employees: | N/A | City: | MIAMI |
| Market Cap: | N/A | IPO Year: | 2024 |
| Target Price: | N/A | AVG Volume (30 days): | 133.6K |
| Analyst Decision: | N/A | Number of Analysts: | N/A |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.56 | EPS Growth: | N/A |
| 52 Week Low/High: | $2.35 - $8.40 | Next Earning Date: | 05-27-2025 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Latest TELOMIR PHARMACEUTICALS INC News
TELO Breaking Stock News: Dive into TELO Ticker-Specific Updates for Smart Investing
ACCESS Newswire
2 hours ago
Telomir Pharmaceuticals Adds Telomir-Ag2 as a Novel Drug Candidate to Pipeline Following Breakthrough Efficacy Against MARSA and Drug-Resistant Infections, Targeting a $30B+ Antimicrobial Market Opportunity
ACCESS Newswire
8 days ago
Telomir Pharmaceuticals Demonstrates Telomir-1 Reverses Key Drivers of Cellular Decline in Human Cell Lines Supporting Therapeutic Potential in Autism and Spasmodic Dysphonia
Zacks Small Cap Research
8 days ago
TELO Announces Promising Aging Reversal Test Results
MT Newswires
2 months ago
Telomir Pharmaceuticals Says Telomir-1 Reduces Tumor Size in Prostate Cancer Animal Model
ACCESS Newswire
2 months ago
Telomir Pharmaceuticals Announces Significant Anti-Cancer Effects in Prostate Cancer Animal Model Using Highly Aggressive Human Prostate Cancer Cells
Zacks Small Cap Research
2 months ago
TELO Study Shows Cancer-Related Breakthrough
ACCESS Newswire
3 months ago
Telomir Pharmaceuticals Announces Breakthrough: Telomir-1 Reverses Calcium Dysregulation, the Hidden Driver of Aging and Disease, in Multiple Human Cell Lines
Simply Wall St.
3 months ago
3 US Penny Stocks To Consider In February 2025
Compare TELO vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "TELO TELOMIR PHARMACEUTICALS INC - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.